文献速递前列腺癌

新型治疗背景下生化复发前列腺癌雄激素剥夺治疗的时机

Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.
PubMed 文献 · J Urol · 2021-05-18

该回顾性研究纳入806例根治性前列腺切除术后生化复发且PSA倍增时间≤10个月的患者,评估延迟至转移时才开始ADT的结局。结果显示,PSA倍增时间<6个月和10个月的患者中位无转移生存期分别为144个月和192个月,中位总生存期分别为168个月和204个月,提示延迟激素治疗的患者生存期较长,需重新评估ADT启动时机。

要点

  • 生化复发且PSA倍增时间≤10个月患者延迟ADT至转移时,无转移生存期和总生存期较长。
  • PSA倍增时间<6个月者中位无转移生存期144个月,10个月者192个月。
  • 需重新评估该人群启动持续ADT的时机。

核心结论

  • 生化复发前列腺癌患者延迟至转移时才开始激素治疗,其无转移生存期和总生存期较长,提示需重新评估主要ADT的启动时机。

研究设计与样本

  • 回顾性综述,纳入约翰霍普金斯医院和沃尔特·里德国家军事医疗中心根治性前列腺切除术后出现生化复发且PSA倍增时间≤10个月的患者806例。

主要发现

  • PSA倍增时间<6个月患者延迟ADT至转移时,中位无转移生存期144个月(95%CI 48-未达到),中位总生存期168个月(95%CI 96-276个月)。
  • PSA倍增时间10个月患者延迟ADT至转移时,中位无转移生存期192个月(95%CI 72-未达到),中位总生存期204个月(95%CI 120-276个月)。

临床怎么用

  • 对于生化复发且PSA倍增时间≤10个月的前列腺癌患者,可考虑延迟持续ADT直至出现转移,但需个体化评估。

局限性

  • 回顾性研究设计,样本来自两家医疗中心,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There were 3 recent U.S. Food and Drug Administration approvals for drugs to be used in nonmetastatic castration resistant prostate cancer, a state that arises from the unproven start of continuous androgen deprivation therapy (ADT) for biochemical recurrent prostate cancer (BCR), before metastatic disease is evident. This report examines the outcome of men with BCR who defer ADT until time of metastasis. MATERIALS AND METHODS: Retrospective review of men diagnosed with clinically localized prostate cancer who underwent radical prostatectomy at Johns Hopkins Hospital and Walter Reed National Military Medical Center and developed BCR with a prostate specific antigen doubling time of not more than 10 months (806 patients). The primary end points were metastasis-free survival and overall survival from time of local treatment among men who delayed ADT until time of metastasis. RESULTS: The median metastasis-free survival of men with BCR and a prostate specific antigen doubling time <6 months and 10 months who delay ADT until metastasis is 144 months (95% CI 48-not reached) and 192 months (95% CI 72-not reached), respectively, with a median overall survival of 168 months (95% CI 96-276 months) and 204 months (95% CI 120-276), respectively. CONCLUSIONS: Metastasis-free survival and overall survival of men with BCR who delay hormone therapy is long. This underscores the need to reevaluate when to start primary ADT in this patient population.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Marshall CH, Chen Y, Kuo C, et al. Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies. J Urol. 2021. PMID: 34003011. doi:10.1097/JU.0000000000001797

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。